Fig 3 - by Tibor M. Szikszay (14439419)

Subjects: “…disproportionate large reduction…”

BLyS^-/- significantly decreased IgM and IgG secreting cells. by Natalie M. Bath (6316517)

Subjects:

SPTAN1 knockdown cells show decreased cell proliferation. by Anne Ackermann (6443975)

“…The shSPTAN1_3 knockdown induced significantly decreased viability after both 24 and 48 h in Caco-2 cells, and after 48 h in SW620 cells. …”

A simplified summary of the results where the difference between baseline and sleep restriction or recovery was found significant. by Jeremi K. Ochab (11372614)

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

Subjects:

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “... by Mobina Faqani (22783963)

ELISA analysis revealed a significant decrease in SP (A & B) and CGRP (C & D) protein levels in the corneas and tear fluid of mice treated with 0.5% bupivacaine (BUP) every alterna... by Ananya Datta (19932144)

Descriptive presentation of the percentage reduction between baseline and post-brushing for planimetric values (Δ%P%D), and for RMNPI values (Δ%RMNPI) averaged over the three teeth... by Nadine Schlueter (755050)

Subjects:

PRISMA flow diagram. by Manik Chhabra (10822587)

Subjects:

Forest plot of comparison of saroglitazar 4mg versus control on LDL-cholesterol (mg/dL). by Manik Chhabra (10822587)

Subjects:

Treatment and outcome characteristics. by Manik Chhabra (10822587)

Subjects:

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2 mg on serum creatinine (mg/dL). by Manik Chhabra (10822587)

Subjects:

Forest plot of comparison of saroglitazar 4mg versus control on total cholesterol (mg/dL). by Manik Chhabra (10822587)

Subjects:

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on LDL-cholesterol (mg/dL). by Manik Chhabra (10822587)

Subjects:

Risk of bias summary. by Manik Chhabra (10822587)

Subjects:

Risk of bias graph. by Manik Chhabra (10822587)

Subjects:

Characteristics of included studies and subjects. by Manik Chhabra (10822587)

Subjects:

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on total cholesterol (mg/dL). by Manik Chhabra (10822587)

Subjects:

The number of gauging cross-sections where a statistically significant decreasing trend was identified. by Krzysztof Kochanek (835532)